Carna Health’s AI Platform Earns Spot on Fortune’s Innovative List

BOSTON, MA – March 25, 2026 – Carna Health, a digital health company focused on transforming the management of kidney disease, has been named to the prestigious Fortune list of America’s Most Innovative Companies 2026. The Boston-based startup secured a spot among the top 100 companies overall, placing it in the top 1% of all organizations evaluated for the honor.

The award, presented by Fortune and the world-leading statistics portal Statista Inc., recognizes Carna Health's significant contributions to healthcare through its pioneering work in Cardio-Kidney-Metabolic (CKM) care. The company, founded in 2021, has distinguished itself by leveraging artificial intelligence to combat the silent progression of chronic kidney disease (CKD) and related conditions, earning particularly high marks in the ranking’s process and culture innovation categories.

"Being recognized on Fortune’s America’s Most Innovative Companies 2026 list is a testament to the incredible work our team at Carna Health is doing to revolutionize the care of Cardio-Kidney-Metabolic Syndrome," said Dr. Salvatore Viscomi, CEO and Co-Founder of Carna Health. "Innovation is at the core of our mission – leveraging AI and global data not only to predict risk progression across all populations, but to equip local clinicians with the tools they need to intervene earlier and more effectively. This honor not only validates our commitment to delivering cutting-edge solutions for patients and motivates us to push the boundaries of what’s possible in digital health."

The AI Engine Revolutionizing Kidney Care

At the heart of Carna Health's recognition is its sophisticated, AI-enabled platform designed to fundamentally change how CKD is detected, monitored, and managed. Chronic kidney disease is a notoriously stealthy condition, often remaining asymptomatic until it has reached advanced stages, by which point treatment options are limited and costly. Carna Health’s technology directly confronts this challenge by enabling early detection and proactive intervention on a massive scale.

The company’s intelligent platform integrates data from both laboratory diagnostics and point-of-care (POC) devices, such as Nova Biomedical's systems that can measure key indicators like creatinine, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (uACR) from small blood and urine samples. This allows for real-time, minimally invasive testing outside traditional hospital settings, bringing crucial health screenings into communities.

Once collected, this data is fed into Carna Health's AI-driven analytics engine. The platform uses predictive algorithms to identify undiagnosed risk, forecast disease progression, and provide actionable insights. This creates a comprehensive "Patient 360" view that empowers healthcare providers—especially primary care physicians in areas with limited access to specialists—to make informed, timely decisions. By moving beyond generic guidelines and providing region-specific insights into disease prevalence, the system helps upskill frontline healthcare teams and democratize specialized knowledge.

The Anatomy of an Innovative Company

The Fortune and Statista ranking is far more than a simple popularity contest; it is based on a rigorous, multi-faceted methodology that evaluates innovation from the inside out. Companies were assessed across three core pillars: product innovation, process innovation, and innovation culture. The process involved extensive surveys of over 37,000 employees and more than 3,000 industry experts, including recruiters and management consultants.

Carna Health’s high scores in process and culture innovation suggest that its forward-thinking approach is deeply embedded in its organizational DNA. The ranking methodology also included a sophisticated analysis of intellectual property portfolios, conducted in partnership with LexisNexis® Intellectual Property Solutions. This involved evaluating not just the quantity but the quality and strength of a company's patents, adding a layer of objective, data-driven validation to the assessment.

For a company founded just five years ago to rank so highly—placing #70 among the 34 recognized healthcare organizations on the list—is a powerful indicator of its strategic execution and internal alignment. This achievement validates the company's focus on building a sustainable culture of innovation that translates directly into groundbreaking products and efficient operational processes.

Tackling a Global Health Crisis, One Community at a Time

The significance of Carna Health's work extends far beyond its technological achievements. The company is tackling one of the most pressing public health crises of our time. CKD affects hundreds of millions of people worldwide and is projected to become the fifth leading cause of death globally by 2040. The disease disproportionately impacts underserved communities and places an enormous economic burden on healthcare systems.

Carna Health has adopted a deliberately global approach to address this challenge. Through strategic partnerships, including a key collaboration with Siemens Healthineers, the company is deploying its platform in emerging markets where the need is greatest. It has already launched successful programs in Bermuda, Cameroon, and Antigua and Barbuda, with further expansion underway in the Philippines and the Dominican Republic. Plans are also in motion to enter the U.S. and Turkish markets, bringing its proven model to a wider audience.

By focusing on prevention and early management, the company is not only improving patient outcomes but also generating significant health-economic benefits. The ability to cost-effectively screen entire populations and intervene before the disease progresses to renal failure represents a paradigm shift from reactive, high-cost treatment to proactive, value-based care. Looking ahead, Carna Health plans to broaden its platform to include integrated care pathways for diabetes and other cardiometabolic conditions, recognizing the deep interconnectedness of these diseases and solidifying its role as a pivotal force in the future of integrated digital healthcare.